← Atlas Theme · spans 1 topics
Subcutaneous non-factor therapies render frequent intravenous infusions for bleeding disorders obsolete.
The clinical and regulatory ascent of subcutaneous, long-acting non-factor therapies is liberating patients with severe bleeding disorders from the heavy burden of frequent intravenous replacement infusions.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
Incyte Bets $2 Billion on Vega Therapeutics to Secure Phase 3 Bleeding Disorder Monoclonal Antibody VGA039 The development of VGA039 aims to replace burdensome, twice-weekly intravenous infusions with a long-acting, subcutaneous monoclonal antibody.
Science & Health
FDA Expands Pfizer’s Hympavzi Approval to Children and Hemophilia Patients with Inhibitors The expanded subcutaneous therapy eliminates the heavy burden of frequent, complex intravenous replacement infusions for hemophilia patients.